BC
PACB icon

Brookfield Corp’s Pacific Biosciences PACB Stock Holding History

Brookfield Corp’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-282,763
Closed -$3.76M – 406
2023
Q2 		$3.76M Buy
282,763
+15,179
+6% +$184K 0.01% 320
2023
Q1 		$3.1M Buy
+267,584
New +$2.66M 0.01% 370

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Brookfield Corp's PACB Position: Q3 2023 in Review

Brookfield Corp sold out of Pacific Biosciences (PACB) in Q3 2023, closing a stake of 282,763 shares — an estimated $3.76M sold.

Brookfield Corp first reported a position in PACB in Q1 2023 and held it in 2 quarters. The position peaked at $3.76M in Q2 2023. 273 funds tracked by Wall St. Rank hold PACB as of Q3 2023.

  • Brookfield Corp reported no remaining Pacific Biosciences position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 282,763 Pacific Biosciences shares in Q3 2023, an estimated $3.76M.
  • Brookfield Corp first reported a position in Pacific Biosciences in Q1 2023 and held it in 2 quarters.
  • Brookfield Corp's Pacific Biosciences position peaked at $3.76M in Q2 2023.
  • 273 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.